Sue Mahony, Ph.D., became president of Lilly Oncology in March 2011. She is also a senior vice president for Eli Lilly and Company and a member of the company’s executive committee.
In May 2009, she was appointed senior vice president, human resources and diversity for Lilly. Previously, she led Lilly’s operations in Canada.
Mahony was born and educated in the United Kingdom, where she obtained a Bachelor of Science degree in pharmacy from Aston University in Great Britain. She obtained her Ph.D. in pharmacy in 1989 in the Cancer Research Campaign Experimental Chemotherapy Group also at Aston University. She then received a master’s degree in business administration in 1998 from the London School of Business. In 2012, Sue received an honorary doctorate from Aston University.
Mahony joined Lilly in 2000 after more than a decade in sales and marketing roles in the United Kingdom and Europe in oncology/hematology and cardiovascular medicine for Schering-Plough, Amgen and Bristol- Myers Squibb. Since joining Lilly, Mahony has held roles in global marketing, product development, Six Sigma and general management, including global brand development leader for duloxetine (Cymbalta®) and fluoxetine (Prozac®).
In 2010, Mahony was recognized as one of the Indianapolis Business Journal’s “Women of Influence.” Mahony has served on the board of the United Way of Central Indiana since 2010. Sue joined the Board of Directors of Park Tudor School in 2015.
Sue and her husband have two children.